1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > CytomX Therapeutics, Inc. - Product Pipeline Review - 2016

CytomX Therapeutics, Inc. - Product Pipeline Review - 2016

  • June 2016
  • -
  • Global Markets Direct
  • -
  • 42 pages

CytomX Therapeutics, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘CytomX Therapeutics, Inc. - Product Pipeline Review - 2016’, provides an overview of the CytomX Therapeutics, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by CytomX Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of CytomX Therapeutics, Inc.
- The report provides overview of CytomX Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses CytomX Therapeutics, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features CytomX Therapeutics, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate CytomX Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for CytomX Therapeutics, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding CytomX Therapeutics, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents

CytomX Therapeutics, Inc. - Product Pipeline Review - 2016
Table of Contents
Table of Contents 2

CytomX Therapeutics, Inc. Snapshot 6
CytomX Therapeutics, Inc. Overview 6
Key Information 6
Key Facts 6
CytomX Therapeutics, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
CytomX Therapeutics, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
CytomX Therapeutics, Inc. - Pipeline Products Glance 12
CytomX Therapeutics, Inc. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
CytomX Therapeutics, Inc. - Drug Profiles 14
CTX-023 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
CTX-033 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
CTX-1003 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
CX-072 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
CX-2009 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
Monoclonal Antibody Conjugate to Target CD-71 for Oncology 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Monoclonal Antibody Conjugate to Target ITGA-3 for Oncology 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
Monoclonal Antibody Conjugated to Target CD3 and EGFR for Solid Tumor 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Monoclonal Antibody Conjugates 1 for Oncology 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
Monoclonal Antibody Conjugates 2 for Oncology 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Monoclonal Antibody to Antagonize CTLA4 for Oncology 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Cellular Immunotherapy for Oncology 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Monoclonal Antibodies 1 for Oncology 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Monoclonal Antibodies 2 for Oncology 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Monoclonal Antibodies for Oncology 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Monoclonal Antibody Conjugates 3 for Oncology 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Monoclonal Antibody Conjugates for Oncology 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Monoclonal Antibody to Antagonize Interleukin-6 Receptor for Inflammation 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Monoclonal Antibody to Antagonize PD-1 for Oncology 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Monoclonal Antibody to Inhibit Glycoprotein-130 for Inflammation 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
CytomX Therapeutics, Inc. - Pipeline Analysis 34
CytomX Therapeutics, Inc. - Pipeline Products by Target 34
CytomX Therapeutics, Inc. - Pipeline Products by Molecule Type 35
CytomX Therapeutics, Inc. - Pipeline Products by Mechanism of Action 36
CytomX Therapeutics, Inc. - Recent Pipeline Updates 37
CytomX Therapeutics, Inc. - Dormant Projects 39
CytomX Therapeutics, Inc. - Locations And Subsidiaries 40
Head Office 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42

List of Tables
CytomX Therapeutics, Inc., Key Information 6
CytomX Therapeutics, Inc., Key Facts 6
CytomX Therapeutics, Inc. - Pipeline by Indication, 2016 8
CytomX Therapeutics, Inc. - Pipeline by Stage of Development, 2016 10
CytomX Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016 11
CytomX Therapeutics, Inc. - Preclinical, 2016 12
CytomX Therapeutics, Inc. - Discovery, 2016 13
CytomX Therapeutics, Inc. - Pipeline by Target, 2016 34
CytomX Therapeutics, Inc. - Pipeline by Molecule Type, 2016 35
CytomX Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016 36
CytomX Therapeutics, Inc. - Recent Pipeline Updates, 2016 37
CytomX Therapeutics, Inc. - Dormant Developmental Projects,2016 39

List of Figures
CytomX Therapeutics, Inc. - Pipeline by Top 10 Indication, 2016 8
CytomX Therapeutics, Inc. - Pipeline by Stage of Development, 2016 10
CytomX Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016 11
CytomX Therapeutics, Inc. - Pipeline by Top 10 Target, 2016 34
CytomX Therapeutics, Inc. - Pipeline by Molecule Type, 2016 35
CytomX Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 36

Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in Denmark

  • January 2017
    6 pages
  • Therapy  

  • Denmark  

View report >

Anti-Infective Market in India

  • January 2017
    4 pages
  • Anti-Infective  

    Blood Disease  

  • India  

    United States  

View report >

Insulin Market and Diabetes Statistics in the US

  • January 2017
    8 pages
  • Insulin  

    Antidiabetics  

    Diabetes  

  • United States  

View report >

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.